QURE Stock Analysis: Uniqure | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.670m USD | 12M Return: -30.7% | NL0010696654 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.6M
Qual. Beats: 0
Rev. Trend: -28.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
uniQure N.V. is a Netherlands-based clinical-stage biotechnology company developing gene therapies for rare and serious diseases, with its U.S. operations focused on conditions like hemophilia B, Huntingtons disease, epilepsy, ALS, and Fabry disease. The companys commercial product, HEMGENIX, is approved for hemophilia B, while its lead pipeline candidate AMT-130 targets Huntingtons disease and is currently in Phase I/II trials. Founded in 1998 and headquartered in Amsterdam, uniQure supplements its internal pipeline through partnerships, including a licensing agreement with Apic Bio for an SOD-1 ALS gene therapy and a development and commercial supply agreement with CLS Behring.
As a gene therapy developer in the rare disease space, uniQure operates in a biotechnology sub-sector where companies often pursue Orphan Drug Designation to secure extended market exclusivity and regulatory support for therapies targeting small patient populations. HEMGENIX, which enables hemophilia B patients to produce their own factor IX, was among the first gene therapies approved by the FDA for a blood disorder, illustrating the companys role in advancing one-time, potentially curative treatments.
- HEMGENIX sales ramp drives near-term revenue growth
- AMT-130 Huntingtons disease Phase II data readout
- Cash runway concerns prompt potential equity offering
| Net Income: -232.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 3.14k% < 20% (prev 3.91k%; Δ -772.2% < -1%) |
| CFO/TA -0.20 > 3% & CFO -192.2m > Net Income -232.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.9m) vs 12m ago 19.46% < -2% |
| Gross Margin: 29.32% > 18% (prev 88.13%; Δ -58.81% > 0.5%) |
| Asset Turnover: 2.21% > 50% (prev 1.77%; Δ 0.43% > 0%) |
| Interest Coverage Ratio: -3.24 > 6 (EBIT TTM -186.3m / Interest Expense TTM 57.5m) |
| A: 0.67 (Total Current Assets 692.5m - Total Current Liabilities 60.1m) / Total Assets 940.6m |
| B: -1.62 (Retained Earnings -1.52b / Total Assets 940.6m) |
| C: -0.20 (EBIT TTM -186.3m / Avg Total Assets 914.5m) |
| D: 0.46 (Book Value of Equity 294.7m / Total Liabilities 645.9m) |
| Altman-Z'' = -1.76 = D |
| DSRI: 0.97 (Receivables 4.80m/3.88m, Revenue 20.2m/15.8m) |
| GMI: 3.01 (GM 88.13% / 29.32%) |
| AQI: 1.49 (AQ_t 0.24 / AQ_t-1 0.16) |
| SGI: 1.28 (Revenue 20.2m / 15.8m) |
| TATA: -0.04 (NI -232.9m - CFO -192.2m) / TA 940.6m) |
| Beneish M = -0.75 (Cap -4..+1) = D |
As of November 22, 2026, the stock is trading at USD 19.35 with a total of 2,104,168 shares traded. Over the past week, the price has changed by -18.73%, over one month by -14.81%, over three months by -60.42% and over the past year by -30.65%.
Current recommended Stop Loss: 15.90 (which is 17.8% or 2 ATR below the current price).
Uniqure has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy QURE.
- StrongBuy: 10
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 59.4 | 207.2% |
P/E Forward = 27.933
P/S = 82.8089
P/B = 5.6653
Revenue TTM = 20.2m USD
EBIT TTM = -186.3m USD
EBITDA TTM = -170.0m USD
Long Term Debt = 50.3m USD (from longTermDebt, last quarter)
Short Term Debt = 2.99m USD (from shortTermDebt, last quarter)
Debt = 74.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.0m
Net Debt = -282.6m USD (calculated: Debt 74.4m - CCE 357.0m)
Enterprise Value = 1.39b USD (1.67b + Debt 74.4m - CCE 357.0m)
Interest Coverage Ratio = -3.24 (Ebit TTM -186.3m / Interest Expense TTM 57.5m)
EV/FCF = -7.04x (Enterprise Value 1.39b / FCF TTM -197.1m)
FCF Yield = -14.21% (FCF TTM -197.1m / Enterprise Value 1.39b)
FCF Margin = -977.5% (FCF TTM -197.1m / Revenue TTM 20.2m)
Net Margin = -1.15k% (Net Income TTM -232.9m / Revenue TTM 20.2m)
Gross Margin = 29.32% ((Revenue TTM 20.2m - Cost of Revenue TTM 14.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev -77.97%)
Tobins Q-Ratio = 1.48 (Enterprise Value 1.39b / Total Assets 940.6m)
Interest Expense / Debt = 77.36% (Interest Expense 57.5m / Debt 74.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -147.2m (EBIT -186.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.44 (Total Current Assets 692.5m / Total Current Liabilities 66.3m)
Debt / Equity = 0.25 (Debt 74.4m / totalStockholderEquity, last quarter 294.7m)
Debt / EBITDA = 1.66 (negative EBITDA) (Net Debt -282.6m / EBITDA -170.0m)
Debt / FCF = 1.43 (negative FCF - burning cash) (Net Debt -282.6m / FCF TTM -197.1m)
Total Stockholder Equity = 241.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.47% (Net Income -232.9m / Total Assets 940.6m)
RoE = -96.34% (Net Income TTM -232.9m / Total Stockholder Equity 241.7m)
RoCE = -63.79% (EBIT -186.3m / Capital Employed (Equity 241.7m + L.T.Debt 50.3m))
RoIC = -16.68% (negative operating profit) (NOPAT -147.2m / Invested Capital 882.4m)
WACC = 13.83% (E(1.67b)/V(1.74b) * Re(14.45%) + (debt cost/tax rate unavailable))
Discount Rate = 14.45% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 97.40 | Cagr: 17.51%
[DCF] Fair Price = unknown (Cash Flow -197.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: -28.57 | Revenue CAGR: -7.18% | SUE: -0.06 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-1.00 | Chg30d=+4.38% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-3.33 | Chg30d=+3.45% | Revisions=+0% | GrowthEPS=-13.8% | GrowthRev=+41.6%
EPS next Year (2027-12-31): EPS=-2.64 | Chg30d=+2.15% | Revisions=+0% | GrowthEPS=+20.8% | GrowthRev=+394.1%
[Analyst] Revisions Ratio: +0% (up=5, down=5)